利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.033 秒)

    Stable and soluble antibodies inhibiting TNF alpha
    2.
    发明授权
    Stable and soluble antibodies inhibiting TNF alpha 有权
    稳定和可溶性抗体抑制TNFα

    公开(公告)号：US09422366B2

    公开(公告)日：2016-08-23

    申请号：US14134779

    申请日：2013-12-19

    申请人： ESBATech, an Alcon Biomedical Research Unit LLC

    发明人： Leonardo Borras ,  Tea Gunde ,  David Urech

    IPC分类号： C07K16/24

    CPC分类号： C07K16/241 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

    摘要： The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

    摘要翻译： 本发明涉及特别稳定和可溶的scFv抗体和对TNF特异性的Fab片段，其包含针对TNF的稳定性，溶解性，体外和体内结合以及低免疫原性而优化的特异性轻链和重链序列。 所述抗体被设计用于诊断和/或治疗TNF介导的病症。 还公开了用于表达本发明的重组抗体的核酸，载体和宿主细胞，用于分离它们的方法和所述抗体在医学中的用途。

    Solubility optimization of immunobinders
    4.
    发明授权
    Solubility optimization of immunobinders 有权

    公开(公告)号：US10221237B2

    公开(公告)日：2019-03-05

    申请号：US15378649

    申请日：2016-12-14

    申请人： ESBATech, an Alcon Biomedical Research Unit LLC

    发明人： Leonardo Borras ,  David Urech

    IPC分类号： C07K16/00 ,  C07K16/24 ,  C07K16/22

    摘要： The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.

    STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA
    7.
    发明申请
    STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA 审中-公开
    稳定和可溶性抗体抑制TNF ALPHA

    公开(公告)号：US20160251428A1

    公开(公告)日：2016-09-01

    申请号：US15157641

    申请日：2016-05-18

    申请人： ESBATech, an Alcon Biomedical Research Unit LLC

    发明人： Leonardo Borras ,  Tea Gunde ,  David Urech

    IPC分类号： C07K16/24

    CPC分类号： C07K16/241 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

    摘要： The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

    摘要翻译： 本发明涉及特别稳定和可溶的scFv抗体和对TNF特异性的Fab片段，其包含针对TNF的稳定性，溶解性，体外和体内结合以及低免疫原性而优化的特异性轻链和重链序列。 所述抗体被设计用于诊断和/或治疗TNF介导的病症。 还公开了用于表达本发明的重组抗体的核酸，载体和宿主细胞，用于分离它们的方法和所述抗体在医学中的用途。